Epogen Biosimilar Jury Verdict May Ignite New 'Safe Harbor' Battle

Amgen awarded $70m in damages after jury finds certain batches of Hospira's Epogen biosimilar infringed a manufacturing process patent; case offers 'juicy legal issue' for Federal Circuit to address.